Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Barni

Showing results (241-250 of 369) with videos related to

Pageof 37
Sort By:
Tumori|December 31, 1993
A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinomaP Lissoni, S Barni, A Ardizzoia, et al.
British Journal of Cancer|November 1, 1996
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patientsP Lissoni, F Paolorossi, G Tancini, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary resultsP Lissoni, S Barni, F Rovelli, et al.
The International Journal of Biological Markers|October 1, 1990
Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndromeP Lissoni, S Barni, G Cattaneo, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 29, 2017
Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studiesG Tomasello, F Petrelli, M Ghidini, et al.
Oncology|January 1, 1992
Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patientsF Brivio, P Lissoni, E Tisi, et al.
Journal of Biological Regulators and Homeostatic Agents|October 1, 1993
Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatoninP Lissoni, S Barni, A Ardizzoia, et al.
Tumori|June 30, 1988
Alteration of opioid peptide circadian rhythm in cancer patientsS Barni, P Lissoni, F Rovelli, et al.
Tumori|April 4, 1998
Concurrent carboplatin/5FU and radiotherapy compared to radiotherapy alone in locally advanced cervical carcinoma: a case-control studyA Colombo, F Landoni, G Cormio, et al.
The International Journal of Biological Markers|July 1, 1989
Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlatedP Lissoni, V Rizzo, S Barni, et al.
Pageof 37

Showing results (241-250 of 369) with videos related to

Sort By:
Pageof 37
Tumori|December 31, 1993
A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinomaP Lissoni, S Barni, A Ardizzoia, et al.
British Journal of Cancer|November 1, 1996
A phase II study of tamoxifen plus melatonin in metastatic solid tumour patientsP Lissoni, F Paolorossi, G Tancini, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary resultsP Lissoni, S Barni, F Rovelli, et al.
The International Journal of Biological Markers|October 1, 1990
Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndromeP Lissoni, S Barni, G Cattaneo, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 29, 2017
Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studiesG Tomasello, F Petrelli, M Ghidini, et al.
Oncology|January 1, 1992
Effects of a preoperative therapy with interleukin-2 on surgery-induced lymphocytopenia in cancer patientsF Brivio, P Lissoni, E Tisi, et al.
Journal of Biological Regulators and Homeostatic Agents|October 1, 1993
Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatoninP Lissoni, S Barni, A Ardizzoia, et al.
Tumori|June 30, 1988
Alteration of opioid peptide circadian rhythm in cancer patientsS Barni, P Lissoni, F Rovelli, et al.
Tumori|April 4, 1998
Concurrent carboplatin/5FU and radiotherapy compared to radiotherapy alone in locally advanced cervical carcinoma: a case-control studyA Colombo, F Landoni, G Cormio, et al.
The International Journal of Biological Markers|July 1, 1989
Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlatedP Lissoni, V Rizzo, S Barni, et al.
Pageof 37